How concentrated is Vertex's revenue, and what happens if key collaborations end?

Revenue is highly concentrated. Novartis accounted for about 49% of 2004 revenue and GlaxoSmithKline for about 19%. The Novartis, Merck and CFFT research collaborations are scheduled to conclude between December 2005 and June 2006, and GlaxoSmithKline can terminate its HIV agreement on 12 months' notice, ending royalty payments. Management has said it needs to sign new collaborations to replace this funding.

Can Vertex fund its operations without raising more capital?

Management said existing funds are sufficient for at least 18 months. It expects Vertex-controlled development spending to rise sharply in 2005, and it projects year-end 2005 cash above $250 million. The company says it may still raise capital through equity or debt if market conditions are favorable, and convertible note conversions could add significant dilution.

What are the main near-term clinical catalysts?

Key 2005 events include interim results from the 14-day Phase Ib trial of VX-950 in hepatitis C (interim analysis in Q2 2005), enrollment completion in the METRO Phase IIb merimepodib study (expected Q2 2005), and results from the 4-week Phase IIa VX-765 psoriasis study (second half of 2005). Pralnacasan's future depends on nonclinical toxicology studies completing in 2005, and VX-385 interim data is expected from GlaxoSmithKline in 2005.

What is the risk from the Kendall Square facility?

Vertex decided not to occupy its roughly 290,000 square foot Kendall Square facility and has subleased only 45,000 square feet. The recorded net liability is $55.8 million on a discounted basis, but if subleases are not found on the assumed terms, obligations could rise toward the full undiscounted lease amount of about $312 million. Sensitivity disclosures show roughly $6.6 million of liability change for a 10% sublease rate difference.

VRTX 10-K FY2004 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed March 16, 2005. Cited figures are marked; the original filing is the authoritative source.

Vertex Pharmaceuticals' FY2004 10-K shows a company still deep in losses but actively restructuring its financing and collaboration model.

Net loss narrowed to $166.2 million^a ($2.12 per share) from $196.8 million in 2003, driven by total revenue rising 49% to $102.7 million, mainly from new collaborations with Merck, Mitsubishi, and CFFT plus higher HIV royalties. Operating expenses remained heavy, with R&D of $192.2 million, and the 2003 restructuring charge ($91.8 million) was followed by a further $17.6 million charge tied to the unoccupied Kendall Square lease. The balance sheet is the key investor concern.

Cash, cash equivalents and marketable securities fell to $392.3 million^b from $583.2 million, stockholders' equity dropped to $35.4 million from $192.8 million, and the company carries $315 million of convertible notes. Management deferred roughly 75% of its debt maturities from 2007 to 2011 through exchanges that lowered the conversion price on the new notes to $14.94, which increases dilution risk. Management guided to a 2005 net loss of $125-135 million before certain charges, revenue of $150-160 million, and R&D of $225-240 million, and said funds are sufficient for at least 18 months.

The investment case rests on pipeline execution rather than current earnings. Near-term catalysts include merimepodib's METRO Phase IIb triple-combination study in hepatitis C, the VX-950 Phase Ib interim analysis, VX-765 psoriasis data, and the pralnacasan toxicology findings. Dependence on Novartis (49%^c of 2004 revenue) and GlaxoSmithKline (19%), the Kendall Square sublease outcome, and a pending securities class action (judgment for Vertex, appeal window through March 25, 2005) are additional risks.

02—Key points

Key Highlights

Revenue rose 49% to $102.7 million in 2004 (from $69.1 million), led by collaborative R&D revenue of $85.4 million and royalties of $17.3 million on Lexiva/Telzir and Agenerase.
Net loss narrowed to $166.2 million, or $2.12 per share, from $196.8 million, or $2.56 per share, in 2003, though the company expects an operating loss to continue beyond 2005.
Cash, cash equivalents and marketable securities declined to $392.3 million from $583.2 million, with operating cash burn of $142.2 million in 2004.
Stockholders' equity fell to $35.4 million from $192.8 million, with an accumulated deficit of $786.2 million.
Debt restructuring: about $232.4 million of 5.75% notes due 2011 were issued in exchange for 2007 notes, with a conversion price of $14.94 that raises future dilution risk; $82.6 million of 5% notes due 2007 remain outstanding.
Kendall Square lease: the company took a $17.6 million restructuring charge in 2004 and carries a $55.8 million net obligation, with total gross lease commitments of up to $312 million if subleasing falls short.
2005 guidance calls for a net loss of $125-135 million (before certain charges), revenue of $150-160 million, R&D of $225-240 million, and year-end cash above $250 million, with liquidity stated as sufficient for at least 18 months.

03—Questions

Frequently Asked Questions

How concentrated is Vertex's revenue, and what happens if key collaborations end?
Revenue is highly concentrated. Novartis accounted for about 49% of 2004 revenue and GlaxoSmithKline for about 19%. The Novartis, Merck and CFFT research collaborations are scheduled to conclude between December 2005 and June 2006, and GlaxoSmithKline can terminate its HIV agreement on 12 months' notice, ending royalty payments. Management has said it needs to sign new collaborations to replace this funding.
Can Vertex fund its operations without raising more capital?
Management said existing funds are sufficient for at least 18 months. It expects Vertex-controlled development spending to rise sharply in 2005, and it projects year-end 2005 cash above $250 million. The company says it may still raise capital through equity or debt if market conditions are favorable, and convertible note conversions could add significant dilution.
What are the main near-term clinical catalysts?
Key 2005 events include interim results from the 14-day Phase Ib trial of VX-950 in hepatitis C (interim analysis in Q2 2005), enrollment completion in the METRO Phase IIb merimepodib study (expected Q2 2005), and results from the 4-week Phase IIa VX-765 psoriasis study (second half of 2005). Pralnacasan's future depends on nonclinical toxicology studies completing in 2005, and VX-385 interim data is expected from GlaxoSmithKline in 2005.
What is the risk from the Kendall Square facility?
Vertex decided not to occupy its roughly 290,000 square foot Kendall Square facility and has subleased only 45,000 square feet. The recorded net liability is $55.8 million on a discounted basis, but if subleases are not found on the assumed terms, obligations could rise toward the full undiscounted lease amount of about $312 million. Sensitivity disclosures show roughly $6.6 million of liability change for a 10% sublease rate difference.

04—Continue

← View all 10-K filings